Novimmune

Novimmune is a biopharmaceutical company based in Geneva, Switzerland. The company specializes in the discovery and development of monoclonal antibodies for the treatment of inflammatory diseases, immune-related disorders, and cancer.

History[edit | edit source]

Novimmune was founded in 1998 by a group of scientists with the aim of developing new therapies for diseases with unmet medical needs. The company has since grown to become a leader in the field of monoclonal antibody development.

Research and Development[edit | edit source]

Novimmune's research and development efforts are focused on the discovery and development of monoclonal antibodies that target key molecules in the immune system. These antibodies are designed to modulate the immune response in a way that is beneficial for the treatment of various diseases.

One of the company's most advanced product candidates is NI-0501, a monoclonal antibody that targets the interferon gamma pathway. This antibody is currently in clinical trials for the treatment of hemophagocytic lymphohistiocytosis, a rare and life-threatening immune disorder.

Partnerships[edit | edit source]

Novimmune has established several partnerships with other biopharmaceutical companies to further the development and commercialization of its product candidates. These partnerships include collaborations with Roche, Genentech, and Tiziana Life Sciences.